Characteristics and outcomes of Bahraini pediatric patients sent abroad for bone marrow transplantation: A ten-year retrospective cohort study

Table 2 Indications of bone marrow transplantation in Bahraini pediatric patients, n (%)

Indications of bone marrow transplantation1	Total, n = 62 (100.0)	Allogeneic, n = 48/61 (77.4)	Autologous, n = 13/61 (21.0)	P value1
Oncological indications	41 (66.1)	27 (56.3)	13 (100.0)	0.002
Acute myeloid leukemia	15 (36.6)	14 (29.2)	0 (0.0)	0.028
Acute lymphoblastic leukemia	11 (26.8)	11 (22.9)	0 (0.0)	0.099
Neuroblastoma	7 (17.1)	0 (0.0)	7 (53.8)	< 0.0001
Hodgkin’s lymphoma	4 (9.8)	1 (2.1)	3 (23.1)	0.028
Wilms tumor	2 (4.9)	0 (0.0)	2 (15.4)	0.043
Mixed germ cell tumor	1 (2.4)	0 (0.0)	1 (7.7)	0.213
Hemophagocytic lymphohistiocytosis	1 (2.4)	1 (2.1)	0 (0.0)	1.000
Hematological indications	21 (33.9)	19 (39.6)	0 (0.0)	0.006
Aplastic anemia	9 (42.3)	8 (16.7)	0 (0.0)	0.184
Beta thalassemia major	5 (23.8)	5 (10.4)	0 (0.0)	0.575
Myelodysplastic syndrome	2 (9.5)	2 (4.2)	0 (0.0)	1.000
Fanconi anemia	2 (9.5)	1 (2.1)	0 (0.0)	1.000
Diamond Blackfan anemia	1 (4.8)	1 (2.1)	0 (0.0)	1.000
Hemoglobin H disease	1 (4.8)	1 (2.1)	0 (0.0)	1.000
Sickle cell disease	1 (4.8)	1 (2.1)	0 (0.0)	1.000
Immunological indications	7 (11.3)	7 (14.6)	0 (0.0)	0.328
Severe combined immunodeficiency	5 (71.4)	5 (10.4)	0 (0.0)	0.575
Chronic granulomatous disease	1 (14.3)	1 (2.1)	0 (0.0)	1.000
X-linked agammaglobulinemia	1 (14.3)	1 (2.1)	0 (0.0)	1.000

¹Fisher’s exact test.